← 홈

ADC

68개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 68개
ADCBiologicstaleMultiple Myeloma Research Conso…Phase 2

Erdafitinib, dexamethasone, ixazomib, pomalidomide (Erdafitinib, dexamethasone, ixazomib, pomalidomide)

Relapsed Refractory Multiple Myeloma · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 ACTIVE
ADCBiologicstaleNational Cancer Institute (NCI)Phase 2

Fexagratinib (Fexagratinib)

Advanced Lymphoma; Advanced Malignant Solid Neoplasm · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 1상태 RECRUITING
ADCBiologicstaleShanghai Miracogen Inc.Phase 1

MRG001 (MRG001)

Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL) · FRα

#FR#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 ACTIVE
ADCBiologicstaleM.D. Anderson Cancer CenterPhase 1

STI-6129 (Part 1, Part 1 (STI-6129))

Refractory T Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia (AML) · FRα

#FR#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+3
임상시험 1상태 DISCONTINUED
ADCBiologicstaleM.D. Anderson Cancer CenterPhase 1

STI-6129 (Part 2, Part 2 (STI-6129))

Refractory T Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia (AML) · FRα

#FR#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+3
임상시험 1상태 DISCONTINUED
ADCBiologicstaleFondazione Italiana Linfomi - E…Phase 2

Pola-R-DHAP (Pola-R-DHAP)

Diffuse Large B Cell Lymphoma Refractory; Diffuse Large B-cell Lymphoma Recurrent · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 1상태 DISCONTINUED
ADCBiologicstaleServier Bio-Innovation LLCPhase 2

S227928 (S227928)

Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML); Myelodysplastic Syndrome (MDS)/AML · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+4
임상시험 1상태 DISCONTINUED
ADCBiologicstaleSorrento Therapeutics, Inc.Phase 1

STI-3258 (STI-3258)

Relapsed Solid Neoplasm; Refractory Cancer · FRα

#FR#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+3
임상시험 1상태 DISCONTINUED

4 / 4 페이지

← 이전다음 →